AbCellera Biologics Inc
ABCL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.69B
Close$
$-4.45
173.9% downside
Current Fair Value
173.9% downsideOvervalued by 173.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.69 Billion |
|---|---|
| Enterprise Value | $1.76 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.49 |
| Beta | 1.2 |
| Outstanding Shares | 303,074,605 |
Return
| Return on Equity | -15.35% |
|---|---|
| Return on Assets | -11.01% |
| Return on Invested Capital | -15.21% |
Valuation & Multiples
| P/E Ratio | -11.52 |
|---|---|
| PEG | 214 |
| Price to Sales | - |
| Price to Book Ratio | 2.01 |
| Enterprise Value to Revenue | 22.21 |
| Enterprise Value to EBIT | -9.18 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$5.68 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$7.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0981▲ 153.76% |
|---|---|
| Total Calls | 1,652,400▲ 44.11% |
| Total Puts | 3,466,900▲ 439.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.61%▲ 5.33% |
|---|---|
| Total Invested | $433.98M▲ 17.10% |
| Investors Holding | 152▼ 3.00% |
ESG Score
No data